BeneVet Oncology Reports Breakthrough Case: Weekly PRV131 Injections and Radiation Lead to Dramatic Tumor Regression in Dog with Aggressive Fibrosarcoma

Press Release - Peabody, MA - May 2025 - BeneVet Oncology, a division of Privo Technologies dedicated to advancing localized cancer therapies for companion animalis is excited to report a dramatic clinical response in a canine patient with a large fibrosarcoma of the right maxilla treated with weekly PRV131 injections in combination with radiation therapy. Read more...




A Waco zoo’s lovebird penguins navigate experimental chemotherapy as a couple

  A Waco zoo’s lovebird penguins navigate experimental chemotherapy as a couple. Read more...




Privo Technologies Announces the Launch of BeneVet: Advancing Companion Animal Health Through Innovation.

Privo Technologies is excited to Launch BeneVet: A company that has been leveraging the technologies developed at Privo over the past 15 years toward treating cancer in companion animals. Read more...